BOULDER, Colo.--(BUSINESS WIRE)--SomaLogic, Inc. and NEC Corporation (TYO: 6701) announced today an agreement that gives NEC exclusive marketing rights in Japan for SomaLogic’s SOMAscan™ assay, which is built on SomaLogic’s proprietary SOMAmer® technology. Under the agreement, NEC will offer access to the SOMAscan assay to biopharmaceutical companies, food companies, and academic research centers for their research in Japan.
SomaLogic’s breakthrough SOMAscan proteomic assay efficiently, accurately, and rapidly identifies and quantifies 1,129 proteins across a wide range of concentrations in small volumes of multiple biological sample types. Compared to other current proteomic technologies, SomaLogic’s breadth and depth of coverage offers unprecedented power for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development.
Help employers find you! Check out all the jobs and post your resume.
